

Saturday, 18 May, 2019

<Room "Amagi"> Morning Seminar 1

Co-Sponsored by Novartis Pharma K.K.

8:00-8:45 **Chair:** Yuzuru Kanakura (*Osaka University Graduate School of Medicine*)

Current Status and Future of CML Treatment

Itaru Matsumura (*Kindai University Faculty of Medicine*)

<Room "Shiosai"> Morning Seminar 2

Co-Sponsored by Pfizer Japan Inc.

8:00-8:45 **Chair:** Hitoshi Kiyoi (*Nagoya University Graduate School of Medicine*)

The Beginning of the New Era of R/R ALL treatment with BESPONSA (Inotuzumab ozogamicin)

Takahiro Yamauchi (*Faculty of Medical Sciences, University of Fukui*)

8:45-8:55

Break (10min)

<Room "Amagi"> Special Session 2

8:55-9:25 **Chair:** Yuzuru Kanakura (*Osaka University Graduate School of Medicine*)

SS-2 My research career in the US medical system

Makio Ogawa (*Medical University of South Carolina, USA*)

9:25-9:40

Break (15min)

<Room "Amagi"> JSH/EHA Joint Session : Normal & Pathologic B Cells

9:40-11:20 **Chairs:** Ulrich Jäger (*Medical University of Vienna, Austria*)

Junji Suzumiya (*Shimane University Hospital*)

9:40-10:05

JSH-EHA-1 Function of memory B cells and their generation mechanism

Tomohiro Kurosaki (*WPI Immunology Frontier Research Center, Osaka University / RIKEN Center for Integrative Medical Sciences (IMS)*)

10:05-10:30

JSH-EHA-2 T cell redirecting strategies in the treatment of B-cell and myeloid malignancies

Hermann Einsele (*University Hospital Würzburg, Germany*)

10:30-10:55

JSH-EHA-3 A germinal center-associated microenvironmental signature predicts clinical outcome of diffuse large B-cell lymphoma

Koji Kato (*Kyushu University Graduate School of Medical Sciences*)

10:55-11:20

JSH-EHA-4 Drug sensitivity testing for treatment-decisions in B-cell-lymphomas

Ulrich Jäger (*Medical University of Vienna, Austria*)

11:20-11:30

Break- Distribute box lunch (10min)

<Room "Amagi"> **Luncheon Seminar 3**

Co-Sponsored by Bristol-Myers Squibb K.K.

11:30-12:15 **Chair:** Koichi Akashi (*Kyushu University Graduate School of Medical Sciences*)

Immunotherapy for multiple myeloma targeting CD38, SLAMF7 and the future

Hermann Einsele (*University of Würzburg, Germany*)

<Room "Shiosai"> **Luncheon Seminar 4**

Co-Sponsored by NIPPON SHINYAKU CO., LTD.

11:30-12:15 **Chair:** Masahiro Kizaki (*Saitama Medical Center, Saitama Medical University*)

Clonal Evolution in Human AML

Ravi Majeti (*Stanford University School of Medicine, USA*)

12:15-12:25

Break (10min)

<Room "Amagi"> **Special Session 3**

12:25-12:55 **Chair:** Koichi Akashi (*Kyushu University Graduate School of Medical Sciences*)

SS-3 Adoptive cell therapy with TCR-Gene engineered T cells and beyond

Hiroshi Shiku (*Mie University Graduate School of Medicine*)